Understanding vitamin D beyond the basics
The research collection
Library
Start with your question
Search the Library
Ask a question in your own words, or look for a particular study.
Need an idea? Try one of these.
Or browse the Library collections below ↓At a Glance
Just want the results or the conclusion?
Open At a Glance on a Library study page for a menu of questions drawn from that paper. Choose Results to see what the researchers found, or Conclusion to read what they think those findings mean.
Find a study
Search above or browse a collection below. Open a paper that interests you.
Choose what to read
Tap a heading in the At a Glance menu to open its answer. Tap it again to close it.
Explore further
Follow the source link to read the passage in context, or use Related reading to find another study.
Try At a Glance in a study
New to the Library?
Start with an abstract for the authors’ short account, or open a full paper to read the study in detail.
Choose your collection
Working demo. The full Library is being prepared.
Full papers
Read the complete studies.
Abstracts
Read the authors’ study abstracts.
Archived full papers
Full papers in the archive.
In preparation
Archived abstracts
Study abstracts in the archive.
In preparation
Secondary full papers
Full papers with secondary relevance to vitamin D.
Secondary abstracts
Abstracts with secondary relevance to vitamin D.
Matching papers
Abstract · 2012
Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4 to 5: a retrospective single center study
From the paper A total of 146 macroalbuminuric patients were identified, and of these, 59 started alfacalcidol treatment during the observation period. A 12% reduction in 24 h albuminuria was seen after starting treatment. In 19 patients with no change in renin-angiotensin-aldosteron-system (RAAS) inhibition, the reduction…
Heart, circulation and kidneys
Abstract · 2016
Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
From the paper A 19% of patients experienced hypocalcemia episodes while an increase of 24% in hyperphosphatemia episodes was observed. A 25% of patients finished cinacalcet before a year of treatment. Main withdrawal reasons were: gastrointestinal and other discomfort (8%), hypocalcaemia (8%), non-compliance (3%), interactions (3%)…
Heart, circulation and kidneys
Abstract · 2021
Effects of active vitamin D on insulin resistance and islet β-cell function in non-diabetic chronic kidney disease patients: a randomized controlled study
From the paper (1) Mean HOMA-IR value: In the ND group, mean HOMA-IR value of the experimental group significantly decreased compared with that of the control group after 3 months of intervention (P = 0.02). In the HD and PD groups, there was no statistical difference…
Metabolism and blood sugar
Abstract · 2017
Effects of the Administration of 25(OH) Vitamin D3 in an Experimental Model of Chronic Kidney Disease in Animals Null for 1-Alpha-Hydroxylase
From the paper Blood calcium remained normal, while phosphate increased significantly. Blood levels of 25(OH)D3 in CYP27B1-/: mice were extremely high compared to those in CYP27B1+/+ animals. CYP27B1+/+ animals with CKD showed increases in TRPV5, TRPV6, calbindinD-28K and calbindinD-9K, which were not further elevated with the…
Heart, circulation and kidneys
Abstract · 2023
Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease: A Comparative Clinical Study
From the paper (1) Background: Hyperphosphatemia is correlated with an increased rate of mortality and morbidity due to cardiovascular diseases in chronic kidney disease (CKD) patients. It can be improved by restricting dietary intake of phosphate and oral phosphate binders, such as lanthanum carbonate and sevelamer…
Heart, circulation and kidneys
Abstract · 2024
Ethnic and seasonal variations in FGF-23 and markers of chronic kidney disease-mineral and bone disorder
From the paper Fibroblast growth factor 23 (FGF-23) and other markers of chronic kidney disease: mineral and bone disorder (CKD-MBD) provide valuable insights into disease processes, treatment options and patient prognosis. However, limited research has explored potential associations with ethnicity or season, particularly in multi-ethnic populations residing…
Bones and muscles
Abstract · 2026
Expanding Outcomes Beyond Chronic Kidney Disease-Mineral and Bone Disorder: A Propensity Score-Matched Analysis of Parathyroidectomy versus Calcimimetics in Dialysis Patients with Secondary Hyperparathyroidism
From the paper We conducted a retrospective multicenter cohort study using the TriNetX research network (2010-2024). Adult dialysis patients with ESRD and severe SHPT, defined by at least one historical intact parathyroid hormone level >600 pg/mL prior to treatment initiation, were included. Patients receiving both therapies…
Bones and muscles
Abstract · 2026
Extended-release calcifediol identifies a therapeutic vitamin D range in chronic kidney disease stages 3 and 4
From the paper Elevation of 25D to 84 ng/ml (range: 66.9 to 102.6 ng/ml) during ERC treatment was associated with a 30% iPTH reduction in participants with SHPT, CKD stage 3 to 4, and VDI. This range was unassociated with adverse changes in mineral metabolism.
Heart, circulation and kidneys
Full papers
Working demo.
Abstracts
Working demo.
Archived full papers
This collection is being prepared.
Archived abstracts
This collection is being prepared.
Related reading
Vitamin D: What It Is
Learn what vitamin D is, how it functions as a regulatory molecule, and why activation, signalling, and biological context matter more than simple measurements.
Read more →